Luke Halpern, Assistant Editor

The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field.

A significant number of patients with high low-density lipoprotein (LDL) cholesterol lack prescribed lipid-lowering medications, highlighting gaps in treatment and care practices.

NS-229 is a Janus kinase 1 (JAK1) inhibitor being investigated in eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that can cause severe allergic and asthmatic symptoms through inflammation of nerve cells.

A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.

New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.

The announcement could ease the burden of prior authorizations on patients, which can cause unnecessary delays for patients receiving prescriptions and serious complications.

Invasive pneumococcal disease trends have fluctuated greatly over the past 2 decades, with older adults remaining at the center of disease burden.

Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.

These results suggest that individuals who are immunocompromised with type 2 diabetes (T2D) may need multiple doses of a pneumococcal conjugate vaccine (PCV) to sustain their protection.

Lauren B. Krupp, MD, FAAN, provides comprehensive guidance on treating pediatric multiple sclerosis, emphasizing early intervention, high-efficacy therapies, and holistic family support.

Multiple phase 3 clinical trials demonstrated dupilumab’s (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.

Lepodisiran, a small interfering RNA, demonstrated cholesterol-lowering effects at 16-mg, 96-mg, and 400-mg doses, with the highest dose being the most effective.

Although the rate of coronary artery lesions decreased across both cohorts of this trial of children with Kawasaki disease, there were no differences in lesion reduction between those receiving intravenous immunoglobulin (IVIG) alone and those receiving IVIG with aspirin.

With a more direct mechanism of action against viral replication compared with standard treatments, the small interfering RNA (siRNA)-based MIR 19 treatment could revolutionize outpatient COVID-19 treatment.

Some patients with aplastic anemia treated with CK0801 achieved durable transfusion independence lasting over 3 years.

Patients who received a pneumococcal 13-valent conjugate vaccination had slightly lower incidence of severe COVID-19 outcomes, but the directions of these associations were mixed.

The new indication expands administration methods for the combination of efgartigimod alfa and hyaluronidase-qvfc, which are already approved for the treatment of some immune-related conditions.

When used in combination with background statin therapy, AZD0780 resulted in major reductions in low-density lipoprotein cholesterol (LDL-C) and achievements of guideline-recommended LDL-C goals.

In a survey among community pharmacists in South Carolina, many pharmacists were unable to correctly identify proper pneumococcal vaccination guideline, raising concerns.

Monetary incentives to receive a COVID-19 vaccine at a public vaccination event may have inadvertently turned away others from receiving a booster, emphasizing the importance of recognizing spillover in trials addressing vaccine hesitancy.

Nilufer Ertekin-Taner contrasts current one-size-fits-all Alzheimer disease treatments with the promise of precision medicine and emphasizes the vital role of collaborative, multidisciplinary care.

The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.

Pharmacy professionals gathered at the American Pharmacists Association 2025 Annual Meeting and Exposition and discussed critical insights in interviews with Pharmacy Times®.

Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.

Pharmacists are essential navigators in the complex landscape of gene therapy.

Kayla Johnson, PharmD, BCPS, BCPP, highlights how integrating pharmacists into neurology clinics drives significant cost savings, high intervention acceptance rates, and improved care coordination.

Stephanie Miller, PhD discusses how artificial intelligence can revolutionize medical research by assisting in drug development and potentially providing more targeted treatments across various diseases.

Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.

Andrew Charles, MD, outlines why calcitonin-gene-related peptide (CGRP) antagonists are increasingly favored as first-line migraine treatments and how pharmacists play a key role in patient education and support.